Goldman Sachs
BCLI

Goldman Sachs’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Goldman Sachs’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,173
Closed -$58K – 6457
2021
Q3 		$58K Sell
1,173
-2,672
-69% -$141K ﹤0.01% 6012
2021
Q2 		$220K Buy
3,845
+2,271
+144% +$121K ﹤0.01% 5694
2021
Q1 		$90K Sell
1,574
-480
-23% -$36.3K ﹤0.01% 5862
2020
Q4 		$139K Buy
+2,054
New +$280K ﹤0.01% 5213
2020
Q3 		– Sell
-1,188
Closed -$200K – 5300
2020
Q2 		$200K Sell
1,188
-671
-36% -$72.3K ﹤0.01% 4794
2020
Q1 		$129K Buy
+1,859
New +$145K ﹤0.01% 4879
2018
Q3 		– Sell
-921
Closed -$54K – 5558
2018
Q2 		$54K Buy
+921
New +$54.2K ﹤0.01% 5340

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's BCLI Position: Q4 2021 in Review

Goldman Sachs sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 1,173 shares — an estimated $58K sold.

Goldman Sachs first reported a position in BCLI in Q2 2018 and held it in 7 quarters. The position peaked at $220K in Q2 2021. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • Goldman Sachs reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 1,173 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $58K.
  • Goldman Sachs first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2018 and held it in 7 quarters.
  • Goldman Sachs's BRAINSTORM CELL THERAPUTC position peaked at $220K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.